Dina M. Flink
About
Dina M. Flink is a scholar working on Oncology, Pathology and Forensic Medicine and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Dina M. Flink has authored 24 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Dina M. Flink's work include CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Cancer survivorship and care (5 papers). Dina M. Flink is often cited by papers focused on CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Cancer survivorship and care (5 papers). Dina M. Flink collaborates with scholars based in United States, Germany and Spain. Dina M. Flink's co-authors include Jeanelle Sheeder, Laxmi A. Kondapalli, Saketh R. Guntupalli, Kian Behbakht, Srikanth Ambati, Carolyn Lefkowits, Aafia Chaudhry, Koji Matsuo, Min Zhu and Jon Arnason and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gynecologic Oncology.
In The Last Decade
Dina M. Flink
23 papers receiving 382 citations
Peers
Dina M. Flink
Samith Sandadi United States
Samuel Shapiro United States
Alexandra C. Istl United States
Mike Radford United Kingdom
Crîngu Antoniu Ionescu Romania
Suna Özdemir Türkiye
İlker Kahramanoğlu Türkiye
Fiona Kew United Kingdom
Sorab Gupta United States
Raquel Molina Spain
Citations per year, relative to Dina M. Flink Dina M. Flink (= 1×)
peers
Samith Sandadi
Countries citing papers authored by Dina M. Flink
Since
Specialization
Citations
This map shows the geographic impact of Dina M. Flink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dina M. Flink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dina M. Flink more than expected).
Fields of papers citing papers by Dina M. Flink
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dina M. Flink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dina M. Flink. The network helps show where Dina M. Flink may publish in the future.
Co-authorship network of co-authors of Dina M. Flink
This figure shows the co-authorship network connecting the top 25 collaborators of Dina M. Flink. A scholar is included among the top collaborators of Dina M. Flink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dina M. Flink. Dina M. Flink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vitolo, Umberto, Michele Merli, Lalita Norasetthada, et al.. (2024). Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).. Journal of Clinical Oncology. 42(16_suppl). TPS7094–TPS7094.
2.
Brouwer‐Visser, Jurriaan, Nathalie Fiaschi, Raquel P. Deering, et al.. (2024). Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Journal for ImmunoTherapy of Cancer. 12(3). e008338–e008338.
3.
Hawkes, Eliza A., Geoffrey Chong, Dina M. Flink, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).. Journal of Clinical Oncology. 42(16_suppl). TPS7093–TPS7093.
4.
Allan, John N., Jennifer L. Crombie, Matthew J. Matasar, et al.. (2024). Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies. Blood. 144(Supplement 1). 3118–3118.
5.
Topp, Max S., Matthew J. Matasar, John N. Allan, et al.. (2024). Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. Blood. 145(14). 1498–1509.
6.
Crombie, Jennifer L., Matthew J. Matasar, Max S. Topp, et al.. (2023). Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study. Blood. 142(Supplement 1). 4461–4461.
7.
Hawkes, Eliza A., Tae Min Kim, Dina M. Flink, et al.. (2023). PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4). HemaSphere. 7(S3). e3061425–e3061425.
8.
Vitolo, Umberto, Elizabeth H. Phillips, Michele Merli, et al.. (2023). PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5). HemaSphere. 7(S3). e49668c2–e49668c2.
9.
Zhu, Min, Kara Olson, Jessica R. Kirshner, et al.. (2022). Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies. Clinical and Translational Science. 15(4). 954–966.
10.
Bannerji, Rajat, John N. Allan, Jon Arnason, et al.. (2020). Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy. Blood. 136(Supplement 1). 42–43.
11.
Guntupalli, Saketh R., Kian Behbakht, Georgina Cheng, et al.. (2020). Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm. JAMA Network Open. 3(6). e207410–e207410.
12.
Brubaker, Lindsay W., et al.. (2019). Pre-operative opioid use in gynecologic oncology: a common comorbidity relevant to the peri-operative period. International Journal of Gynecological Cancer. 29(9). 1411–1416.
13.
Blake, Erin A., Dina M. Flink, Annie A. Yessaian, et al.. (2019). Non-prescription cannabis use for symptom management amongst women with gynecologic malignancies. Gynecologic Oncology Reports. 30. 100497–100497.
14.
Guntupalli, Saketh R., Jeanelle Sheeder, Georgina Cheng, et al.. (2019). 15 Oral apixaban compared to subcutaneous enoxaparin for thromboprophylaxis in women undergoing surgery for suspected gynecologic cancer: final results of a multi-institutional randomized, controlled trial. A9.1–A9.
15.
Flink, Dina M., et al.. (2018). Radiation therapy is not an independent risk factor for decreased sexual function in women with gynecologic cancers. Reports of Practical Oncology & Radiotherapy. 23(5). 331–336.
16.
Flink, Dina M., Laxmi A. Kondapalli, & Yvonne Kellar‐Guenther. (2017). Priorities in Fertility Decisions for Reproductive-Aged Cancer Patients: Fertility Attitudes and Cancer Treatment Study. Journal of Adolescent and Young Adult Oncology. 6(3). 435–443.
17.
Guntupalli, Saketh R., Jeanelle Sheeder, Yevgeniya Ioffe, et al.. (2017). Sexual and Marital Dysfunction in Women With Gynecologic Cancer. International Journal of Gynecological Cancer. 27(3). 603–607.
18.
Flink, Dina M., Jeanelle Sheeder, & Laxmi A. Kondapalli. (2016). Do Patient Characteristics Decide if Young Adult Cancer Patients Undergo Fertility Preservation?. Journal of Adolescent and Young Adult Oncology. 6(2). 223–228.
19.
Flink, Dina M., Jeanelle Sheeder, & Laxmi A. Kondapalli. (2016). A Review of the Oncology Patient's Challenges for Utilizing Fertility Preservation Services. Journal of Adolescent and Young Adult Oncology. 6(1). 31–44.
20.
Guntupalli, Saketh R., Dina M. Flink, Yevgeniya Ioffe, et al.. (2015). Sexual and marital dysfunction in women with gynecologic cancer: Results of a multi-institutional, cross-sectional trial. Gynecologic Oncology. 137. 51–51.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Samith Sandadi Breakdown of academic impact, for papers by Samuel Shapiro Breakdown of academic impact, for papers by Alexandra C. Istl Breakdown of academic impact, for papers by Mike Radford Breakdown of academic impact, for papers by Crîngu Antoniu Ionescu Breakdown of academic impact, for papers by Suna Özdemir Breakdown of academic impact, for papers by İlker Kahramanoğlu Breakdown of academic impact, for papers by Fiona Kew Breakdown of academic impact, for papers by Sorab Gupta Breakdown of academic impact, for papers by Raquel Molina